Alivus Life Sciences Ltd · NSE:ALIVUS

Alivus Life Sciences — Glenmark Life Sciences — Q1 FY23 Earnings Presentation

19 slides from Alivus Life Sciences's earnings presentation, Aug 4, 2022

  1. Slide 1: Glenmark Life Sciences exchange filing cover letter

    G qlenmaRk LIFE SCIENCES Purtnersl1ip lnnowition ~ns.c.1on August 04, 2022 To, To, Dy.General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai - 400

  2. Slide 2: Q1 FY23 Investor Presentation

    Q1 FY23 Investor Presentation Glenmark Life Sciences Ltd G qlenma~k LIFE SCIENCES

  3. Slide 3: Financial Performance Review

    01 Financial Performance Review 2 G qlenma~k LIFE SCIENCES

  4. Slide 4: Q1 FY23 – Highlights

    Q1 FY23 – Highlights • Revenue decreased by 6.7% YoY. However, excluding COVID products, Dr. Yasir Rawjee Revenue growth at 6.5% YoY. Managing Director & INR 4,899 mn Chief Executive Officer • Gross margin improved to 53.3% driven by booking of PLI scheme “We are pleased with our performance in this

  5. Slide 5: P&L Highlights – Q1 FY23

    P&L Highlights – Q1 FY23 Amounts in INR Millions Q1 FY23 Q4 FY22 QoQ Q1 FY22 YoY FY22 Revenue from Operations 4,898.7 5,140.6 -4.7% 5,249.0 -6.7% 21,232.1 Gross Profit 2,609.7 2,589.3 0.8% 2,655.2 -1.7% 10,803.3 Gross Profit (%) 53.3% 50.4% 50.6% 50.9% Other Income 94.9 50.9 39.9 147.0 Employee Bene

  6. Slide 6: Quarter on Quarter Performance

    Quarter on Quarter Performance Sustaining a profitable growth trajectory despite cost & supply chain headwinds ------------------------------------ 5,618 ------------------------------------ 28.7% 31.9% 37 . 0% 31.3% 5,249 5,225 5,141 30.2% 28.6% 32 . 0% 4,899 1,500 27 . 0% 22 . 0% 17 . 0% 1,644 1,6

  7. Slide 7: Financial Performance Track Record

    Financial Performance Track Record Robust growth and profitability indicators over the years ------------------------------------- ------------------------------------~ 35 . 0% CAGR 15.3% 31.5% 31.4% 21,232 6,000 30.6% 29.7% 18,852 27.6% 30 . 0% 5,000 15,373 14,050 25 . 0% 4,000 12,017 6,308 5,919 2

  8. Slide 8: Strong Returns Indicators

    Strong Returns Indicators ----------------------------- ROICE -- ----------------------------- Fixed Assets Turnover -- ------------------------ Working Capital Days 40% FY19 FY20 FY21 FY22 Q1 FY23 3.3 3.4 350 250 202 37% 2.9 3.0 300 176 200 173 168 36% 2.7 250 152 35% 150 200 98 104 99 106 150 89 1

  9. Slide 9: Business Performance Review

    02 Business Performance Review 8 G qlenma~k LIFE SCIENCES

  10. Slide 10: Segment Performance

    Segment Performance 5,047 490 4,803 4,715 435 Revenue (₹ Mn) 4,590 406 Revenue (₹ Mn) 4,448 389 243 Generic API > Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 I_CDMO _) Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 • Generic API revenues in Q1FY23 decreased 1 • CDMO revenues decreased by 37.6% in 95% 7.4% YoY

  11. Slide 11: Market and Therapeutic Area Mix

    Market and Therapeutic Area Mix 27% 24% 27% 28% 33% 34% 28% 37% 35% 43% 6% 4% 4% 4% 8% 6% 7% 10% 3% 4% 15% 10% 14% 18% 14% 73% 76% 73% 72% 67% 40% 39% 37% 37% 43% Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Therapeutic .....__________) Market Mix ■ Regulated Marke

  12. Slide 12: Company Overview

    03 Company Overview 11 G qlenma~k LIFE SCIENCES

  13. Slide 13: Global Footprint

    Global Footprint Filed 436 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 60+ 350+ 30+ 88 103 151 10+ 17 120+ 10+ 50+ 15 62 (Brazil) India – Mix of Regulated Number of Number of customers Regulated Markets Emergi

  14. Slide 14: Quality-focused, compliant manufacturing & R&D infrastructure

    Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity (Jun-22) Last USFDA Inspection Date Approvals Mahape, Navi Mumbai USFDA, MHRA (UK), FIMEA  R&D for new product development (Finland), Romania (Europe) and complex

  15. Slide 15: R&D Capabilities

    R&D Capabilities 650 5.0% 572 550 4.5% Cumulative Filing Status 4.0% 450 400 405 North 376 3.5% Therapy Europe Japan Brazil Australia ROW Total America 2.7% 3.1% 2.7% 2.6% 350 3.0% CVS 36 30 4 16 9 26 121 250 2.1% 2.5% CNS 35 19 7 12 1 11 85 154 2.0% Diabetes 9 3 - 7 - 11 30 150 1.5% Pain Management

  16. Slide 16: Strategy Going Forward

    15 04 Strategy Going Forward G qlenma~k 15 LIFE SCIENCES

  17. Slide 17: Strategic Growth Levers

    Strategic Growth Levers •New product launches •Ramp up CDMO portfolio •Geographical expansion •Expand into complex API platforms •Focus on new markets becoming •Iron compounds more regulated •Oncology •Pursue 2nd source opportunities with top generic players New Gx API Growth Business levers Operati

  18. Slide 18: Future Capacity Expansion Plan

    Future Capacity Expansion Plan Expansion Type Division Location Current Capacity Status & Planned Capacity Operational Timelines Under Construction Brownfield API Dahej 141.9 KL Q2 FY23 4 Modules -240 KL Under Construction Brownfield Intermediate Ankleshwar 550.2 KL Q3 FY23 400 KL Under Construction

  19. Slide 19: For further information contact

    For further information contact Email: complianceofficer@glenmarklifesciences.com Ernst & Young LLP – Investor Relations Diwakar Pingle Email: Diwakar.Pingle@in.ey.com Rahul Thakur Email: rahul.thakur@in.ey.com Mobile: +91 98333 19957 Corporate Office:4th Floor, OIA House, 470, Cardinal Gracious Road,

Glenmark Life Sciences — Q1 FY23 Earnings Presentation on 6ix